SAT0093 CDAI AND DAS28 IN THE MANAGEMENT OF RHEUMATOID ARTHRITIS IN CLINICAL PRACTICE

Satoshi Takanashi(Keio University), Tsutomu Takeuchi(Keio University), Yoko Kaneko(Keio University)
Annals of the Rheumatic Diseases
June 1, 2020
10.1136/annrheumdis-2020-eular.1377
Cited by 1

Related Papers

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
|Annals of the Rheumatic Diseases|2022|1.9k
2022 update
|Radboud Repository (Radboud University)|2010|1.6k
Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis
|Annals of the Rheumatic Diseases|2007|413
NAK is an IκB kinase-activating kinase
|Nature|2000|374